ライフサイエンスコーパス: RIF

1 RIF binding was monitored using absorbance at 525 nm to

2 RIF-1 belongs to the small and poorly explored class of

3 RIF-1 has extraordinary potency (femtomolar, or 10(-15)

4 RIFs are characterized by the local recruitment of DNA d

5 molecule, dubbed rosette-inducing factor 1 (RIF-1), produced by the Gram-negative Bacteroidetes bact

6 Additionally, 11 RIF-sensitive and 25 RIF-resistant clinical isolates wer

7 urprisingly much smaller at higher doses: 15 RIF/Gy after 2 Gy exposure compared to approximately 64

8 Additionally, 11 RIF-sensitive and 25 RIF-resistant clinical isolates were tested by the TB ID

9 r 2 Gy exposure compared to approximately 64 RIF/Gy after 0.1 Gy.

10 The RPH enzyme is a RIF-inactivating phosphotransferase and represents a new

11 ion/resolution rates, we observe an absolute RIF yield that is surprisingly much smaller at higher do

12 together with RIF (period 1), 4 weeks after RIF discontinuation (period 2), and after the RAL dose r

13 tially then 400 mg twice daily 4 weeks after RIF discontinuation.

14 ions to RMP may recover its efficacy against RIF(R) TB.

15 EFV and RIF-based tuberculosis therapy coadministration was asso

16 strated drug-drug interaction between FA and RIF, which lowered FA levels to a degree that could infl

17 erial subpopulations are similar for INH and RIF treatment: mostly intracellular with extracellular b

18 suppression in patients on EFV (600 mg) and RIF-based tuberculosis treatment in the multicenter rand

19 rial tissues taken from patients with RM and RIF.

20 visible detection of both RIF-sensitive and RIF-resistant strains of M. tuberculosis.

21 ve (including rifampin [RIF] susceptible and RIF resistant), and nontuberculosis mycobacterial materi

22 itivity for detection of M. tuberculosis and RIF resistance, including in AFB-negative sputum, and ha

23 teric conflicts that essentially prevent any RIF binding.

24 are of immediate public health importance as RIF+ABZ are registered drugs and thus immediately implem

25 middle domain, which is involved in binding RIF.

26 chip that permits visible detection of both RIF-sensitive and RIF-resistant strains of M. tuberculos

27 ChIP) assays revealed that PXR activation by RIF disrupted enhancer-promoter communication and prompt

28 sis of interactions of RMP with three common RIF(R) mutant RNAPs suggests that modifications to RMP m

29 Interference with these fluid lipid domains (RIFs) perturbs overall lipid homeostasis and affects mem

30 ly small decreases in AUC0-12 and C12 during RIF coadministration, warranting further evaluation in p

31 hat occurs before formation of the ternary E-RIF-NADPH complex.

32 ), which is found upstream of genes encoding RIF-inactivating enzymes from a diverse collection of ac

33 l biopsies (n = 115) from women experiencing RIF and healthy controls.

34 An FA/RIF pharmacokinetic interaction has not previously been

35 label randomized study, we evaluated oral FA/RIF vs standard-of-care (SOC) intravenous antibiotics fo

36 Fourteen subjects were randomized 1:1 to FA/RIF or SOC.

37 ere obtained for 6 subjects randomized to FA/RIF.

38 Here we show that a rosette inducing factor (RIF-1) produced by A. machipongonensis belongs to the sm

39 ating sulfonolipid rosette-inducing factors (RIFs) to recapitulate the full bioactivity of live Algor

40 f women with recurrent implantation failure (RIF) and recurrent miscarriages (RM).

41 Recurrent implantation failure (RIF) is a condition whereby couples fail to achieve preg

42 rriage (RM), recurrent implantation failure (RIF) or fertile controls.

43 ic membrane regions with increased fluidity (RIFs).

44 he average number of radiation-induced foci (RIF) per cell increased over the first 3 h after radionu

45 ibility) for first-line agents was 95.0% for RIF (132/139), 98.2% for INH (111/113), and 98.6% for EM

46 ng to side effects were 35% for INH, 21% for RIF, and 10% for RPT/INH.

47 iduals (7.0% for rifampin [RIF] and 9.3% for RIF or isoniazid [INH]).

48 7.1%/97.1%, 98.2%/97.8%, and 96.5%/97.5% for RIF and 94.4%/96.4%, 95.4%/98.8%, and 94.9%/97.6% for IN

49 0.3%/98.5%, 90.3%/98.5%, and 92.0%/98.5% for RIF resistance detection and 89.1%/99.4%, 89.1%/99.4%, a

50 V2 and Nipro to Hain V1 was demonstrated for RIF and INH resistance detection in isolates and sputum

51 The double dose of RAL overcompensated for RIF induction, but the standard dose was associated with

52 Sensitivity for RIF-resistant M. tuberculosis in AFB-negative sputum was

53 Overall microarray specificity for RIF, INH, and EMB combined was 97.2% (384/395).

54 positive and negative predictive values for RIF, INH, and EMB combined were 84.9% and 98.3%, respect

55 kely resulting in the decreased affinity for RIFs.

56 ates that this retrieval-induced forgetting (RIF) phenomenon reflects inhibitory mechanisms called in

57 This rectangular ion funnel (RIF) was initially evaluated by ion simulations, fabrica

58 Furthermore, RIF resistance was genetically distinct, suggesting poss

59 ed a heretofore unknown RIF resistance gene, RIF phosphotransferase (rph).

60 High RIF and INHP levels were retained in MDM for >15 d follo

61 RPH orthologs are widespread and found in RIF-sensitive bacteria, including Bacillus cereus and th

62 ys, we confirmed that the RAE is involved in RIF-responsive regulation.

63 nregulated and upregulated, respectively, in RIF-treated ShP51 cells, and these regulations were conf

64 e further showed that addition of MTZ to INH/RIF effectively treated animals with active TB within 2

65 MTB/RIF C(T) is a poor surrogate of load in extrapulmonary s

66 similar sensitivity to laboratory-based MTB/RIF (292 [83%] of 351; p=0.99) but higher specificity (9

67 nd 82 (6%) of 1411 with laboratory-based MTB/RIF failed (p=0.22).

68 34 (5%) of 744 tests with point-of-care MTB/RIF and 82 (6%) of 1411 with laboratory-based MTB/RIF fa

69 Point-of-care MTB/RIF had higher sensitivity than microscopy (154 [83%] of

70 The utility of the GeneXpert MTB/RIF (Xpert) assay for detection of Mycobacterium tubercu

71 replacing microscopy with the GeneXpert MTB/RIF (Xpert) nucleic acid amplification assay could reduc

72 GeneXpert MTB/RIF (Xpert), a novel, semiautomated TB nucleic-acid ampl

73 with tuberculosis through the GeneXpert MTB/RIF assay to identify patients with multidrug-resistant

74 available diagnostics, and the GeneXpert MTB/RIF assay when available before inclusion.

75 ed the reporter phage assay to GeneXpert MTB/RIF for detection of M. tuberculosis and rifampin (RIF)

76 city were compared to those of GeneXpert MTB/RIF with an M. tuberculosis culture as the reference sta

77 GeneXpert MTB/RIF-confirmed patients with rifampicin-susceptible tuber

78 ty (TTP; a surrogate of bacterial load), MTB/RIF TB-specific and internal positive control (IPC)-spec

79 in days) was the strongest associate of MTB/RIF positivity in each fluid.

80 ssociated with a decreased likelihood of MTB/RIF-positivity in pulmonary specimens but an increased l

81 compartments, is the main determinant of MTB/RIF-positivity rather than PCR inhibition.

82 We assessed the utility of Xpert((R)) MTB/RIF (GeneXpert) as a screening tool for medical admissio

83 nd NaCl, and the cycle thresholds of the MTB/RIF assay were compared between treated and untreated sa

84 o reduced dropout (15 [8%] of 185 in the MTB/RIF group did not receive treatment vs 28 [15%] of 182 i

85 e microscopy group, more patients in the MTB/RIF group had a same-day diagnosis (178 [24%] of 744 vs

86 56 were similar (320 [43%] of 744 in the MTB/RIF group vs 317 [42%] of 758 in the microscopy group; p

87 y, more culture-positive patients in the MTB/RIF group were on treatment due to reduced dropout (15 [

88 ar microscopy group vs 2 [0.25-3] in the MTB/RIF group; p=0.85) or 6 months (1 [0-3] vs 1 [0-3]; p=0.

89 (182 culture positive) and 744 to Xpert MTB/RIF (185 culture positive).

90 cterial culture, smear microscopy, Xpert MTB/RIF (Cepheid Inc.), tuberculin skin test (TST), and ches

91 pecimens were also tested with the Xpert MTB/RIF (GXP) assay.

92 pulmonary tuberculosis (PTB) using Xpert MTB/RIF (Mycobacterium tuberculosis/rifampicin) automated te

93 The Xpert MTB/RIF (Xpert) assay is a rapid nucleic acid amplification

94 The Xpert MTB/RIF (Xpert) assay is becoming a principal screening tool

95 The Xpert MTB/RIF (Xpert) assay offers rapid and accurate diagnosis of

96 The Xpert MTB/RIF (Xpert) assay permits rapid near-patient detection o

97 Xpert MTB/RIF (Xpert) detects rifampicin-resistant tuberculosis (R

98 he rollout of one such diagnostic, Xpert MTB/RIF (Xpert) is being considered, but if Xpert is used ma

99 ompared the diagnostic accuracy of Xpert MTB/RIF (Xpert) with microscopy for detection of pulmonary t

100 ore sensitive diagnostics, such as Xpert MTB/RIF (Xpert), is still limited by costs.

101 sis in HIV-infected children using Xpert MTB/RIF (Xpert).

102 M, ELISA a sensitivity of 43%, and Xpert MTB/RIF a sensitivity of 100% and specificities of 87%, 91%,

103 M, ELISA a sensitivity of 38%, and Xpert MTB/RIF a sensitivity of 86% and specificities of 70%, 91%,

104 effects of different algorithms of Xpert MTB/RIF and light-emitting diode (LED) fluorescence microsco

105 fampicin susceptibility results of Xpert MTB/RIF and mycobacteria growth indicator tube (MGIT) were c

106 WHO recommends Xpert MTB/RIF as initial diagnostic testing for tuberculous mening

107 microscopy has been replaced with Xpert MTB/RIF as the initial diagnostic test for tuberculosis.

108 ated the sensitivity analysis with Xpert MTB/RIF as the reference standard.

109 a M. tuberculosis assay, the Gene Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA), and a line probe ass

110 ests for tuberculosis, such as the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA), are being imple

111 lification testing (NAAT) with the Xpert MTB/RIF assay (Xpert) may be more efficient and less costly.

112 Xpert MTB/RIF assay (Xpert) on 1, 2, or 3 specimens may be more ef

113 ecificity precludes the use of the Xpert MTB/RIF assay as a biomarker for monitoring tuberculosis tre

114 sitivity and specificity of of the Xpert MTB/RIF assay compared with microscopy in the diagnosis of p

115 The Xpert MTB/RIF assay detected an extra 28 tuberculosis cases compar

116 The Xpert MTB/RIF assay detected rifampicin resistance in three GLA sa

117 ith that of sputum culture and the Xpert MTB/RIF assay for all patients and subgroups of patients str

118 by Patel and colleagues using the Xpert MTB/RIF assay for diagnosis.

119 comparison, the sensitivity of the Xpert MTB/RIF assay for molecular detection of M. tuberculosis DNA

120 We have evaluated the Xpert MTB/RIF assay for the diagnosis of Mycobacterium tuberculosi

121 re examined by smear, culture, and Xpert MTB/RIF assay for the presence of M. tuberculosis and blood

122 sults as a reference standard, the Xpert MTB/RIF assay had high sensitivity (97.0%, 95% CI 95.8-97.9)

123 y assessed the practicality of the Xpert MTB/RIF assay in a real-life setting with high prevalence of

124 ntages and challenges of using the Xpert MTB/RIF assay in areas where tuberculosis is endemic.

125 The Xpert MTB/RIF assay is a commercially available real-time PCR that

126 Analyses of GLA samples with the Xpert MTB/RIF assay is a sensitive and specific method for rapid d

127 The Xpert MTB/RIF assay is an automated molecular test that has improv

128 The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic

129 l quality assessment (EQA) for the Xpert MTB/RIF assay is part of the quality system required for cli

130 Although the development of the Xpert MTB/RIF assay is undoubtedly a landmark event, clinical and

131 The Xpert MTB/RIF assay is useful for rapid diagnosis of childhood tub

132 at the quantitative outputs of the Xpert MTB/RIF assay may be useful as a dynamic measure of TB treat

133 sceptibility (MODS) culture or the Xpert MTB/RIF assay might be used to expand bacteriological diagno

134 The Xpert MTB/RIF assay performed well in both HIV-infected and -uninf

135 The Xpert MTB/RIF assay performs better than smear microscopy in an in

136 e positive in 6 eyes, and the Gene Xpert MTB/RIF assay results were positive in 4 eyes.

137 y and very high specificity of the Xpert MTB/RIF assay supports its inclusion in the reference standa

138 y of the Gene drive to that of the Xpert MTB/RIF assay using M. tuberculosiscultures as the reference

139 Sensitivity of the Xpert MTB/RIF assay was assessed with the Pearson chi(2) or Fisher

140 Mycobacterial culture and Xpert MTB/RIF assay were performed on sputum from children with pe

141 sensitivity and specificity of the Xpert MTB/RIF assay were similar: sensitivity was 68.8% (95% CI 53

142 sensitivity and specificity of the Xpert MTB/RIF assay with GLA samples for the detection of pulmonar

143 fluorescence smear microscopy, the Xpert MTB/RIF assay, mycobacterial growth indicator tube (MGIT) cu

144 The Xpert MTB/RIF assay, which enables simultaneous detection of Mycob

145 us assay, and in 1 eye by the Gene Xpert MTB/RIF assay.

146 resistance detected by the Cepheid Xpert MTB/RIF assay.

147 in large volumes of blood with the Xpert MTB/RIF assay.

148 ug-susceptibility testing, and the Xpert MTB/RIF assay.

149 ugation method and tested with the Xpert MTB/RIF assay.

150 culture (gold-standard test), and Xpert MTB/RIF assays (Cepheid, Sunnyvale, CA, USA) and urine sampl

151 enerated tables to nurse-performed Xpert MTB/RIF at the clinic or sputum smear microscopy.

152 Xpert MTB/RIF can be accurately administered by a nurse in primary

153 and the ability to transfer to the Xpert MTB/RIF cartridge.

154 antitative M tuberculosis DNA with Xpert MTB/RIF correlated with smear grades (rho=-0.74; p<0.0001),

155 combining same-day microscopy and Xpert MTB/RIF could reduce annual TB mortality by 44% relative to

156 Xpert MTB/RIF cycle threshold values are a measure of sputum mycob

157 f immunosuppression as measured by Xpert MTB/RIF cycle threshold values.

158 pulmonary TB cases, respectively; Xpert MTB/RIF detected 5 additional culture-negative cases.

159 Studies investigating Xpert MTB/RIF diagnostic performance on cerebrospinal fluid (CSF)

160 Among TB culture-positive cases, Xpert MTB/RIF had 100% and 81% sensitivity in sputum smear-positiv

161 While molecular tools like Xpert MTB/RIF have advanced our ability to detect Mycobacterium tu

162 We aimed to assess the impact of Xpert MTB/RIF implementation on the delay to treatment initiation

163 d immunosorbent assay (ELISA), and Xpert MTB/RIF in cerebrospinal fluid (CSF) in an autopsy cohort of

164 y and positive predictive value of Xpert MTB/RIF in culture-negative but clinically diagnosed PTB was

165 g, which raised the sensitivity of Xpert MTB/RIF in detecting rifampicin resistance to 93.8%.

166 Five cases were false-positive by Xpert MTB/RIF in patients with nontuberculous mycobacteria, old PT

167 Xpert MTB/RIF is an effective tool in diagnosing PTB but will be m

168 ting and spinning), LAM ELISA, and Xpert MTB/RIF on the CSF samples.

169 MGIT, MODS and Xpert MTB/RIF on the initial specimen identified 40/51 (78%), 33/5

170 ment, population-level scale-up of Xpert MTB/RIF or microcolony-based culture often averted 10 times

171 104 true positive (culture and/or Xpert MTB/RIF positive) specimens.

172 7 culture-negative specimens were Xpert MTB/RIF positive.

173 excluded, strongly suggesting all Xpert MTB/RIF positives are true positives.

174 tality following implementation of Xpert MTB/RIF possibly because of insufficient powering, differenc

175 Xpert MTB/RIF reduced median days-to-TB detection for all TB cases

176 Xpert MTB/RIF results for 740 CSF samples from 698 patients across

177 The Xpert MTB/RIF results over time were compared with the results of

178 Patients with positive LAM or Xpert MTB/RIF results were referred for tuberculosis treatment.

179 When Xpert MTB/RIF results were used as the reference standard, sensiti

180 The determinants of Xpert MTB/RIF sensitivity, a widely used PCR test for the diagnosi

181 Xpert MTB/RIF specificity was 100% (99.7-100%) among 1164 specimen

182 randomized to two strategies: (1) Xpert MTB/RIF test (Cepheid, Sunnyvale, CA) performed at a distric

183 The Xpert MTB/RIF test for tuberculosis is being rolled out in many co

184 ict hospital laboratory or (2) POC Xpert MTB/RIF test performed at a primary health care clinic.

185 rmat extends the capability of the Xpert MTB/RIF test, enabling up to 20 ml of blood to be tested rap

186 ially with the introduction of the Xpert MTB/RIF test, used for tuberculosis (TB) diagnosis for all p

187 Sputum samples were collected for Xpert MTB/RIF testing and culture.

188 aims to introduce EQA concepts for Xpert MTB/RIF testing and evaluates five potential EQA panels.

189 d clinical effect of point-of-care Xpert MTB/RIF testing at primary-care health-care facilities in so

190 ommendation results in unnecessary Xpert MTB/RIF testing in many individuals living in tuberculosis-e

191 els showed good compatibility with Xpert MTB/RIF testing, and none showed PCR inhibition.

192 two years of same-day microscopy, Xpert MTB/RIF testing, and the combination of both approaches.

193 wenstein-Jensen (LJ) cultures, and Xpert MTB/RIF testing.

194 Scaling up Xpert MTB/RIF to all centralized laboratories to achieve 75% popul

195 diagnostic performance of the new Xpert MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis.

196 Xpert MTB/RIF Ultra (Xpert Ultra) was developed to overcome this l

197 The newer Xpert MTB/RIF Ultra cartridge has shown improved sensitivity in re

198 The sensitivity of MGIT, MODS and Xpert MTB/RIF was 88%, 71% and 76%, respectively, among all 104 tr

199 reduction in positivity rates with Xpert MTB/RIF were slower than those with the standard methods.

200 We prospectively compared MODS and Xpert MTB/RIF with standard microscopy and culture using the BD MG

201 iologically confirmed cases and 41 Xpert MTB/RIF(R) and culture negative cases.

202 with positive specimens tested by Xpert MTB/RIF) and (2) TBDx alone-against the gold standard liquid

203 ecting smear-negative cases (e.g., Xpert MTB/RIF) further improves the incremental benefit of these d

204 es (i.e., same-day microscopy plus Xpert MTB/RIF) generated synergistic effects: an 18.7% reduction i

205 (95% CI, 60.6% to 74.6%); and for Xpert MTB/RIF, 91.0% (95% CI, 85.0% to 94.8%).

206 direct fluorescent AFB smear, SMF, Xpert MTB/RIF, and MGIT culture media.

207 sis in South Africa were tested by Xpert MTB/RIF, concentrated smear microscopy, and liquid culture t

208 diagnostic test for tuberculosis, Xpert MTB/RIF, received a conditional programmatic recommendation

209 Xpert MTB/RIF, the first automated molecular test for tuberculosis

210 rt, by the success and roll out of Xpert MTB/RIF, there is now considerable interest in new technolog

211 estimated for SMF, AFB smear, and Xpert MTB/RIF, using MGIT as the reference standard.

212 Xpert MTB/RIF-confirmed rifampin-susceptible tuberculosis cases we

213 Xpert MTB/RIF-generated cycle-threshold (C(T)) values have poor cl

214 the composite standard, including Xpert MTB/RIF-positive cases.

215 aining, mycobacterial culture, and Xpert MTB/RIF.

216 fugation may increase the yield of Xpert MTB/RIF.

217 c acid amplification tests such as Xpert MTB/RIF.

218 system), and 174 (84%) of 207 with Xpert MTB/RIF; at 26 weeks, positive results were obtained for ten

219 ssay performed on a sputum sample (Xpert MTB/RIF; repeated if first result was negative).

220 13 [6%] vs 22/268 [8%]; p=0.38) or Xpert-MTB/RIF assay (13/89 [15%] vs 20/138 [14%]; p=0.98).

221 Notably, nanoformulated RIF and INHP were found to be localized in recycling and

222 Coadministration of nanoformulated RIF and INHP provided a 6-fold increase in therapeutic e

223 By using the RAE as a probe for new RIF-associated genes in several actinomycete genomes, we

224 odal groups, the cathodal group exhibited no RIF.

225 L mutation and two other frequently observed RIF(R) mutants, RpoB D516V and RpoB H526Y.

226 Phi(2)GFP10, in the presence and absence of RIF, and bacilli were enumerated using FACS.

227 functional impact on RNAP in the absence of RIF.

228 hia depletion following 7-day combination of RIF+ABZ also led to accelerated macrofilaricidal activit

229 Completion of RIF and RPT/INH for LTBI in an HCW population is more li

230 e images measures the local concentration of RIF in the thin tissue section.

231 sed live imaging and mathematical fitting of RIF kinetics to show that RIF induction rate increases w

232 fumarate and lamivudine after initiation of RIF (10 mg/kg/day).

233 Long-acting nanoformulations of RIF and an INH derivative, pentenyl-INH (INHP), were pre

234 ocatalytic activity towards the oxidation of RIF, under the optimal conditions.

235 signature containing 303 genes predictive of RIF.

236 logs defined the absolute stereochemistry of RIF-1 and revealed a remarkably restrictive set of struc

237 Here, we report a modular total synthesis of RIF-1 stereoisomers and structural analogs.

238 weeks 4, 8, 16, 24 on-RIF and weeks 4, 8 off-RIF.

239 in was 1.96 microg/mL on-RIF versus 1.80 off-RIF (P = .067).

240 were significantly higher on-RIF versus off-RIF in blacks (2.08 vs 1.75, P = .005).

241 ommends an EFV dose increase for patients on RIF weighing >/=50 kg.

242 odeficiency virus (HIV)-infected patients on RIF-based antitubercular therapy in the French National

243 hours post-EFV dose at weeks 4, 8, 16, 24 on-RIF and weeks 4, 8 off-RIF.

244 Cmin were significantly higher on-RIF versus off-RIF in blacks (2.08 vs 1.75, P = .005).

245 Weight >/=60 kg on-RIF, compared to <60 kg, was associated with lower EFV C

246 Median Cmin was 1.96 microg/mL on-RIF versus 1.80 off-RIF (P = .067).

247 At later time points, RIF numbers diminished, along with dropping dose rates,

248 mples shows that the gene signature predicts RIF with 100% positive predictive value (PPV).

249 Increased occurrence of Rifamycin-resistant (RIF(R) ) TB, approximately 41% of which results from the

250 Rifampicin (RIF) induces UGT1A1, an enzyme involved in raltegravir (

251 gnane X receptor (PXR) activator rifampicin (RIF), human hepatocellular carcinoma HepG2-derived ShP51

252 tocytes to the human PXR agonist rifampicin (RIF) on expression of target genes involved in phase I (

253 bacterium tuberculosis (MTB) and rifampicin (RIF) resistance, was endorsed by WHO in December, 2010.

254 ls with a combination of INH and rifampicin (RIF) was highly effective at preventing reactivation dis

255 f the natural product antibiotic rifampicin (RIF) to 2'-N-hydroxy-4-oxo-rifampicin, a metabolite with

256 ave developed a tissue model for rifampicin (RIF), an antibiotic used to treat tuberculosis, and have

257 ighly sensitive determination of rifampicin (RIF) by square wave adsorptive stripping voltammetry.

258 t synergized with minocycline or rifampicin (RIF) to deplete symbionts, block embryogenesis, and stop

259 Co-therapy with rifampicin (RIF) and isoniazid (INH) used to treat tuberculosis in h

260 Rifampin (RIF) upregulates CYP 450 isoenzymes, potentially lowerin

261 r detection of M. tuberculosis and rifampin (RIF) resistance in sputum.

262 DST (true resistance) was 100% for rifampin (RIF) (14/14), 90.0% for isoniazid (INH) (36/40), 70% for

263 reptomycin (STR), isoniazid (INH), rifampin (RIF), ethambutol (EMB) (collectively known as SIRE), and

264 testing (DST) to isoniazid (INH), rifampin (RIF), moxifloxacin (MOX), ofloxacin (OFX), amikacin (AMK

265 d 9-month isoniazid (INH), 4-month rifampin (RIF), weekly rifapentine/isoniazid (RPT/INH) for 12 week

266 1 [V1]) for the rapid detection of rifampin (RIF) and isoniazid (INH) resistance.

267 administration of combinations of rifampin (RIF), isoniazid [isonicotinylhydrazine (INH)], pyrazinam

268 ly conserved regulatory motif, the rifampin (RIF) -associated element (RAE), which is found upstream

269 oB) gene that confer resistance to rifampin (RIF), the treatment of choice for tuberculosis (TB).

270 ntly associated with patients with rifampin (RIF)-resistant TB.

271 n (PJI), often in combination with rifampin (RIF).

272 HIV-infected individuals (7.0% for rifampin [RIF] and 9.3% for RIF or isoniazid [INH]).

273 negative, MTBC-positive (including rifampin [RIF] susceptible and RIF resistant), and nontuberculosis

274 oresistance in 1 patient (0.3%), and INH-S + RIF-S in 220 (68.3%) patients.

275 eptible to rifampicin and isoniazid (INH-S + RIF-S).

276 ociated expression signature also stratifies RIF patients into distinct groups with different subsequ

277 Rosette-induction assays using synthetic RIF-1 stereoisomers and naturally occurring analogs defi

278 FAD only when RIF is present, implying that RIF binds before NADPH in the catalytic scheme.

279 matical fitting of RIF kinetics to show that RIF induction rate increases with increasing radiation d

280 tion of the expression changes suggests that RIF is primarily associated with reduced cellular prolif

281 The RIF naphthoquinone blocks access to the FAD N5 atom, imp

282 The RIF provided a 2-fold sensitivity increase without signi

283 The RIF was integrated to a SLIM-time of flight (TOF) MS sys

284 The strength of the RIF associated expression signature also stratifies RIF

285 e S531L mutant exhibits a disordering of the RIF binding interface, which effectively reduces the RMP

286 , certainly the electrostatic surface of the RIF binding pocket is dramatically changed, likely resul

287 ing parameters, including RF, DC bias of the RIF electrodes, and electric fields for effectively inte

288 In contrast, the H526Y mutation reshapes the RIF binding pocket, generating significant steric confli

289 bitory processes could be causally linked to RIF.

290 Total RIF resistance indicative of MDR-TB in treatment-naive p

291 applied for the determination of ultra-trace RIF amounts in biological and pharmaceutical samples wit

292 genomes, we identified a heretofore unknown RIF resistance gene, RIF phosphotransferase (rph).

293 NADPH efficiently reduces the FAD only when RIF is present, implying that RIF binds before NADPH in

294 ng radiation dose, whereas the rate at which RIFs disappear decreases.

295 n of FA exposure if used in combination with RIF should be a topic of future research.

296 resolution structure of RIFMO complexed with RIF represents the precatalytic conformation that occurs

297 not support weight-based dosing of EFV with RIF.

298 weeks after initiation of RAL together with RIF (period 1), 4 weeks after RIF discontinuation (perio

299 more likely to have completed treatment with RIF (P < .0001) or RPT/INH (P < .0001) than INH.

300 mouse model, we found that co-treatment with RIF and INH causes accumulation of the endogenous hepato

301 1 and EMT-like morphological changes without RIF treatment.

302 Chest radiography or Xpert RIF/MTB, delivered through maternal care services, were